Mar 10, 2009 - Sepracor Inc. today announced that it has entered into a Settlement and License Agreement with Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc., a wholly owned subsidiary of Teva, to resolve the patent litigation against Barr involving Sepracor's XOPENEX brand levalbuterol HCl Inhalation Solution products (1.25 mg/3 mL, 0.63 mg/3 mL and 0.31 mg/3 mL) and to grant a license to Barr and Teva. The agreement permits Barr and Teva to launch generic versions of these XOPENEX Inhalation Solution dosages under terms of a non-exclusive license commencing on February 17, 2013.
The details can be read here.
No comments:
Post a Comment